/
OCGN
$1.67+$0.17 (+11.33%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$507.8M
339M shares
52-week range
$0.90 – $2.73
42% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
10.33%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-6.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $43.0K | $0 | $2.5M | $6.0M | $4.1M | $4.4M |
| Cost of revenue | $49.6K | $8.1M | $6.4M | $0 | $0 | $704.0K | $2.0M | $2.4M |
| Gross profit | −$49.6K | −$8.1M | −$6.3M | $0 | $2.5M | $5.3M | $2.1M | $2.0M |
| Gross margin | — | — | -14676.7% | — | 100.0% | 88.3% | 51.5% | 45.9% |
| R&D | $15.6M | $8.1M | $13.4M | $35.1M | $56.2M | $39.6M | $32.1M | $39.8M |
| Operating income | −$30.1M | −$14.2M | −$21.3M | −$58.0M | −$89.1M | −$65.5M | −$54.8M | −$62.9M |
| EBITDA | −$14.4M | −$14.1M | −$14.2M | −$58.1M | −$86.3M | −$62.4M | −$52.1M | −$60.3M |
| Net income | −$8.6M | −$20.2M | −$21.8M | −$58.4M | −$86.8M | −$63.1M | −$54.1M | −$67.8M |
| Net margin | — | — | -50748.8% | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (diluted) | -13.98 | -1.53 | -0.31 | -0.30 | -0.40 | -0.26 | -0.20 | -0.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-0.23 | $-0.26–$-0.18 | 5 |
| 2027 | $11M | $-0.24 | $-0.27–$-0.19 | 4 |
| 2028 | $209M | $0.10 | $-0.29–$0.61 | 4 |
| 2029 | $582M | $0.74 | $0.12–$1.55 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ocugen, Inc. Common Stock
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
www.ocugen.com- Employees
- 116
- IPO / List date
- Dec 3, 2014
- HQ
- MALVERN, PA
Held by traders on TradeandTell
No one on the platform currently holds OCGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 1,700,400 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OCGN yet.
